Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines

JIARUI WANG, HUILING WANG, LONG ZHAO, SUFANG FAN, ZHONGHAI YANG, FEI GAO, LIXIA CHEN, GARY GUISHAN XIAO, JOSEPH MOLNÁR and QI WANG
Anticancer Research September 2010, 30 (9) 3593-3598;
JIARUI WANG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HUILING WANG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LONG ZHAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUFANG FAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZHONGHAI YANG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FEI GAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIXIA CHEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GARY GUISHAN XIAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEPH MOLNÁR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
QI WANG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wqdmu@yahoo.com.cn
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To investigate whether down-regulation of P-glycoprotein (P-gp) is correlated to resistance to cisplatin and VP-16 in four histopathological subtype cell lines of lung cancer (SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446). Materials and Methods: After pretreatment with or without verapamil, the P-gp expression was examined by means of RT-PCR and immunofluorescence. Cell survival on treatment with cisplatin and VP-16 was determined by MTT assay. Results: The expression of P-gp was clearly inhibited by verapamil in all four cell lines. Following pretreatment with verapamil, NCI-H-446 was more sensitive to cisplatin, while SPCA-1, NCI-H-460 and NCI-H-446 were more sensitive to VP-16 compared to the control. Conclusion: Down-regulation of P-gp is associated with intrinsic resistance to cisplatin in the NCI-H-446 and to VP-16 in SPCA-1, NCI-H-460 and NCI-H-446 cell lines. These findings indicate that down-regulation of P-gp may be helpful for the reversion of drug resistance in some lung cancer cell line subtypes.

  • Lung cancer
  • drug resistance
  • P-glycoprotein
  • down-regulation

Lung cancer is one of most prevalent types of cancer and the leading cause of cancer mortality in the world (1). Chemotherapy treatment for lung cancer prolongs patient survival, but drug resistance, and especially intrinsic multidrug resistance, limit the chance of successful chemotherapy (2). Resistance to anticancer agents is frequently observed both in small cell lung cancer (SCLC) and in non-small cell lung cancer (NSCLC) (3).

Resistance to chemotherapy is mediated via a range of cellular alterations including reduced drug accumulation, changes in the level of protein targets, mutations that diminish the binding of the drug to the target, increased trapping of the drug in acidic vesicles, alterations in the metabolism of drugs, increased tolerance of cellular damage and diminished apoptotic signaling (4, 5). The reduction of drug accumulation occurs through a series of proteins, among which P-glycoprotein (P-gp) is the most important P-gp, encoded by the MDR1 gene, is a 170 kDa phosphorylated glycoprotein and a member of the ATP-binding cassette (ABC) superfamily of membrane transporters (6). In tumor cells, the overexpression of P-gp is responsible for the efflux of various hydrophobic chemotherapeutic agents from the cells, which decreases their intracellular accumulation and leads to a low efficacy of chemotherapy and to multidrug resistance (7). P-gp is localized in the plasma membrane of resistant cancer cells, and can bind and transport a great variety of structurally and functionally unrelated antitumor drugs, such as vinblastine, vincristine, doxorubicin, daunorubicin, VP-16, teniposide, paclitaxel and many others in an ATP-dependent manner (8, 9). It has been suggested that P-gp is one of the important factors in the intrinsic chemoresistance of lung cancer cells (10).

P-gp appears to be involved in drug resistance in human cancer; it is therefore an urgent matter to find mediators which can reverse the drug resistance mediated by P-gp (11). Verapamil, a phenylalkylamine L-type calcium channel antagonist, is a first-generation inhibitor of P-gp. It has been reported that verapamil can inhibit the expression of P-gp in several P-gp-positive cell lines, including human leukaemic, hamster lung cancer and human breast cancer cell lines (12-14). However, few studies relate to human lung cancer, and particularly to different histopathological subtypes. The aim of this study, therefore, was to investigate the expression of P-gp pretreated by verapamil and the effect of the down-regulation of P-gp in intrinsic drug resistance to cisplatin and VP-16 in different histopathological subtypes of lung cancer cell lines [squamous carcinoma, adenocarcinoma, large cell lung cancer (LCLC) and (SCLC)].

Materials and Methods

Cell culture and treatment. Histopathological subtypes of four human lung cancer cell lines, SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446 (squamous carcinoma, adenocarcinoma, LCLC and SCLC, respectively), were obtained from the American Type Culture Collection (Manassas, VA, USA). SK-MES-1 was maintained in EMEM (GIBICO, Carlsbad, CA, USA), and SPCA-1, NCI-H-460 and NCI-H-446 were cultured in RPMI-1640 medium (HyClone, Logan, UT, USA), supplemented with 10% foetal bovine serum (FBS) at 37°C in a humidified atmosphere containing 5% CO2. Before the experiments, the cells of each histopathological type were divided into an experimental group and a control group, depending on the addition of verapamil (10 μM; Sigma, St.Louis, MO, USA) or not for 24 h. All experiments were performed with exponentially growing cells and were repeated at least 3 times.

RNA isolation and RT-PCR. Total RNA extraction and RT-PCR were carried out as previously described (15). In brief, total cytoplasmic RNA was extracted from the cells of the two groups by using RNAiso plus (TaKaRa, Japan) according to the manufacturer's instructions. RT-PCR was performed with an RNA PCR Kit (AMV, Ver.3.0, TaKaRa, Japan). The housekeeping gene GAPDH was used as an internal control to confirm equal loading in each experiment and was amplified from the same cDNAs. The primers specific to MDR1 and GAPDH are shown in Table I. Reverse transcription was performed at 50°C for 30 minutes, and terminated at 99°C for 5 minutes and 5°C for 5 minutes. The cDNA generated from this experiment was then subjected to PCR to amplify the P-gp transcript. The PCR cycle started with 1 cycle of 3 minutes at 94°C, 33 cycles of 45 seconds at 94°C, 45 seconds at 58°C, and 1 minute at 72 °C; this was followed by a final incubation at 72°C for 15 minutes. A total of 5 μl of PCR product was separated on a 2% agarose gel and stained with ethidium bromide for visualization. The relative abundance of each PCR product was determined by quantitative analysis of digital photographs of gels, using Labworks 4.6 software (UVP Products, Upland, CA, USA). The integral optical density (IOD) values of MDR1 and GAPDH were measured. The ratio IODMDR1/IODGAPDH was used to represent the relative mRNA level of P-gp.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Sequence of primers and products for RT-PCR.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

IC50s of cisplatin and VP-16 in verapamil-pretreated and untreated lung cancer cell lines.

Immunofluorescence. The cells in the exponential phase were dispensed onto the coverglass in 6-well plates at a density of 1×105 cells per well. The cells of the two groups were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min, and permeabilized in PBS containing 0.1% Triton X-100 and 5% bovine serum albumin (BSA) for 1 h before the detection of P-gp with immunofluorescence. The media, with anti-P-gp goat polyclonal antibody (Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA) at a dilution of 1:400, were introduced into the culture chamber and the cells were incubated at 4°C overnight. After being washed with PBS three times, the cells were stained with anti-goat fluorescein isothiocyanate (FITC) green-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.) at a dilution of 1:200 at 37°C for 1 h. Cell images were subsequently captured with a fluorescence microscope and analyzed by using Northern exposure image analysis/archival software (Mississauga, Ontario, Canada).

Cell viability assay. Cell viability was measured with the MTT assay (16). Briefly, cells in the exponential phase were dispensed in 96-well plates overnight at a density of 1×104 cells per well. The cells were incubated with cisplatin or VP-16 at different concentrations (cisplatin: 0, 2, 4, 6 and 8 μM; VP-16: 0, 20, 40, 60 and 80 μM) and after a 48-h incubation, 20 μl of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) reagent was added into each well and cultured at 37°C in a 5% CO2 incubator for 4 h. The medium was discarded, 100 μl of dimethyl sulfoxide (DMSO) were added into each well, and the mixture was incubated for 10 min. The optical density of each well was measured with a Multiskan Ascent (Thermo Fisher Scientific, MA, USA). For analysis, the sensitivity to cisplatin and VP-16, the cell viability and IC50 were calculated via the following equations: cell viability=mean optical density of the anticancer drug-treated group/mean optical density of the control group×100%; IC50=concentration of cisplatin/VP-16 at 50% cell viability.

Statistical analysis. All data are given as means±SE. Statistical comparisons were made by using the independent-samples t-test. All analyses were performed with SPSS 16.0 software. A p value of <0.05 (CI: 95%) was considered to indicate statistical significance.

Results

Down-regulation of P-gp by verapamil at the mRNA level in different lung cancer cell lines. To examine the effect of verapamil on MDR1 mRNA expression, RT-PCR analysis was carried out on the four cell lines pretreated with or without verapamil. As shown in Figure 1, verapamil pretreatment caused a decrease in P-gp at the mRNA level in all four cell lines. As compared with the control group, there was a significant decrease in the verapamil-pretreated group for all four cell lines, the result being ~0.6- to 8-fold lower than that for the control group (all p values<0.05). However, the levels of reduction observed for the cell lines differed. For example, MDR1 for NCI-H-446 was ~8-fold lower than that for the control group (0.06±0.01 vs. 0.47±0.03), whereas the reduction was only 0.6-fold for the SK-MES-1 cell line (0.34±0.04 vs. 0.56±0.07).

Downregulation of P-gp by verapamil at the protein level in different lung cancer cell lines. To investigate whether the down-regulation of P-gp at the mRNA level was related to its protein expression for the cells pretreated with verapamil, immunofluorescence assays were carried out on the four cell lines that were additionally pretreated with or without verapamil. As shown in Figure 2, the immunofluorescence results demonstrated that P-gp was localized on the membranes of the cells. Similarly to the P-gp mRNA results, the fluorescence intensity of the pretreated cells was clearly weaker than that of the control group for all four cell lines. The normalized fluorescence intensities per cell in the experimental group were ~2- to 3-fold lower than that of the control group (17.26±1.93 vs. 36.34±1.32, 17.52±3.68 vs. 33.46±1.63, 18.49±1.01 vs. 47.89±4.13 and 16.44±1.01 vs. 47.87±5.15 for SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446 cell lines, respectively, all p-values <0.05, CI: 95%).

Effects of down-regulation of P-gp on the resistance to cisplatin and VP-16 in different lung cancer cells. To determine the effects of the down-regulation of P-gp on the resistance to cisplatin and VP-16 in the four cell lines, the cell viabilities were determined by MTT assay, and the IC50s of cisplatin and VP-16 for the cell lines pretreated with or without verapamil were calculated. As shown in Table II and Figure 3, in comparison with the control group, verapamil pretreatment caused a significant decrease in the IC50 of cisplatin only in the NCI-H-446 cell line (3.33±0.24 vs. 4.74±0.38, p<0.05, CI: 95%), and not in the other three cell lines. The IC50 of VP-16 significantly decreased in the verapamil-pretreated cell lines of SPCA-1 (50.69±2.25 vs. 67.39±4.3), NCI-H-460 (45.79±4.47 vs. 62.37±2.88) and NCI-H-446 (43.61±1.64 vs. 56.35±3.15), all p-values<0.05 (CI: 95%), but not for the SK-MES-1 cell line. This indicated that the down-regulation of P-gp is associated with the resistance to cisplatin in the NCI-H-446 cell line and to VP-16 in the SPCA-1, NCI-H-460 and NCI-H-446 cell lines.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

RT-PCR results for MDR1 mRNA in four cell lines pretreated with or without verapamil. at 10 μM for 24 h (experimental or control group) (SK-MES-1/V, SPCA-1/V, NCI-H-460/V and NCI-H-446/V, pretreated with verapamil). Bar graph showing the relative levels of P-gp mRNA evaluated by using the ratio IOD MDR1/IOD GAPDH for the four cell lines. *p<0.05 relative to control group (CI: 95%).

Discussion

Drug resistance remains a major challenge for successful cancer chemotherapy (17). P-gp is one of the possible causes of drug resistance and failure of cancer chemotherapy (18). Methods to overcome the drug resistance mediated by P-gp are therefore desirable. This has led to the development of inhibitors during the past two decades (19). In the present study, the effects of verapamil on the expression of P-gp,the correlation between the down-regulation of P-gp and the resistance to cisplatin and VP-16 in lung cancer cell histopathological subtypes were investigated. The results demonstrated that verapamil inhibited the expression of P-gp significantly in all the four cell lines, at both mRNA and protein levels. The down-regulation of P-gp increased the chemosensitivity to cisplatin in the NCI-H-446 cell line, and to VP-16 in the SPCA-1, NCI-H-460 and NCI-H-446 cell lines. The findings indicated that verapamil is an effective inhibitor of P-gp, and the down-regulation of P-gp is associated with chemoresistance to cisplatin and VP-16 in lung cancer.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

P-gp immunofluorescence results for the cell lines SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446 pretreated with or without verapamil. A, control group; B, pretreated with verapamil. The average expression of P-gp per cell reflected by normalized fluorescence intensities decreased on pretreatment with verapamil (II). The normalized fluorescence intensity per cell was determined as the number of cells in a region divided by the fluorescence intensity in that region. *p<0.05 relative to the control group (CI: 95%).

Thus, the current study revealed that verapamil inhibits the expression of P-gp in human lung squamous carcinoma, adenocarcinoma, LCLC and SCLC cell lines (SK-MES-1, SPCA-1, NCI-H-460 and NCI-H-446), indicating that verapamil is potentially an appropriate inhibitor of P-gp in lung cancer. Many other reports have described that verapamil can inhibit the expression of P-gp. Sulova et al. (14) found that verapamil induced a depression of P-gp expression in the vincristine resistance cell line L1210/VCR. Takara et al. (12) reported that verapamil can decrease the expression of P-gp in the HeLa cell subline Hvr100-6, mainly via the down-regulation of P-gp mRNA. As concerns the mechanism, Hosey considered that verapamil can block L-type calcium channels and also alter the Na+-Ca2+ exchanger transport activity (20). This may induce alterations in calcium homeostasis and affect the expression of P-gp (14, 20). However, the current study indicated that the degree of P-gp reduction differed for the four cell lines pretreated with verapamil, which suggested that selection of the inhibitor of P-gp should be based on the lung cancer cell line subtype.

The accumulated evidence indicates that P-gp is associated with chemotherapy resistance to many anticancer drugs, such as vincristine, doxorubicin, actinomycin D, mitomycin C, cisplatin and VP-16 (21-24). The current study revealed that the down-regulation of P-gp was able to increase the chemosensitivity to cisplatin in the SCLC cell line (NCI-H-446) and to VP-16 in the adenocarcinoma, LCLC and SCLC cell lines (SPCA-1, NCI-H-460 and NCI-H-446). Similarly to the current results, Triller et al. (22) observed that the expression of P-gp correlated with the resistance to cisplatin in SCLC cells. Murphy et al. also found that P-gp plays an important role in the resistance to VP-16 in SCLC and NSCLC cell lines (25). All these data demonstrate that P-gp-mediated resistance is important in lung cancer chemotherapy. The mechanisms of resistance to cisplatin or VP-16 mediated by P-gp are possibly similar: with the energy derived from ATP, P-gp can bind and transport the anticancer drug out of the cells, so as to decrease the intracellular concentration of the drug and lead to drug resistance (26). The different responses to the two drugs among the various subtypes of lung cancer may be related to the specific characteristics of each cell. Further investigations on the possible mechanism of cisplatin resistance in NSCLC may therefore be of benefit for the treatment of human lung cancer.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

IC50 values of cisplatin (A) and VP-16 (B) for four cell lines pretreated with or without verapamil (10 μM) for 24 h as MTT viability assay. *p<0.05 relative to control group.

In conclusion, verapamil significantly inhibited the expression of P-gp in all four investigated cell lines. The down-regulation of P-gp is associated with resistance to cisplatin in the NCI-H-446 cell line and to VP-16 in the NCI-H-460, SPCA-1 and NCI-H-446 cell lines. These findings indicate that the down-regulation of P-gp may be helpful for the reversion of drug resistance in some lung cancer cell subtypes.

Acknowledgements

This work was supported by the National Nature Science Foundation of China (30470464, 30670532).

Footnotes

  • ↵* These Authors contributed equally to this work.

  • Received April 27, 2010.
  • Revision received May 29, 2010.
  • Accepted June 4, 2010.
  • Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Cohen V,
    2. Khuri FR
    : Chemoprevention of lung cancer: current status and future prospects. Cancer Metastasis Rev 21: 349-362, 2002.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Ihde DC,
    2. Minna JD
    : Non-small cell lung cancer. Part II: Treatment. Curr Probl Cancer 15: 105-154, 1991.
    OpenUrlPubMed
  3. ↵
    1. Nishio K,
    2. Nakamura T,
    3. Koh Y,
    4. Suzuki T,
    5. Fukumoto H,
    6. Saijo N
    : Drug resistance in lung cancer. Curr Opin Oncol 11: 109-115, 1999.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Jemal A,
    2. Siegel R,
    3. Ward E,
    4. Murray T,
    5. Xu J,
    6. Thun MJ
    : Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Gottesman MM
    : Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627, 2002.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ambudkar SV,
    2. Kimchi-Sarfaty C,
    3. Sauna ZE,
    4. Gottesman MM
    : P-glycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485, 2003.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Fuqua SA,
    2. Moretti-Rojas IM,
    3. Schneider SL,
    4. McGuire WL
    : P-glycoprotein expression in human breast cancer cells. Cancer Res 47: 2103-2106, 1987.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Sugimoto Y,
    2. Tsuruo T
    : DNA-mediated transfer and cloning of a human multidrug-resistant gene of adriamycin-resistant myelogenous leukemia K562. Cancer Res 47: 2620-2625, 1987.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hamada H,
    2. Tsuruo T
    : Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Doyle LA
    : Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20: 326-337, 1993.
    OpenUrlPubMed
  11. ↵
    1. Tsuruo T
    : Molecular cancer therapeutics: recent progress and targets in drug resistance. Intern Med 42: 237-243, 2003.
    OpenUrlPubMed
  12. ↵
    1. Takara K,
    2. Sakaeda T,
    3. Tanigawara Y,
    4. Nishiguchi K,
    5. Ohmoto N,
    6. Horinouchi M,
    7. Komada F,
    8. Ohnishi N,
    9. Yokoyama T,
    10. Okumura K
    : Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci 16: 159-165, 2002.
    OpenUrlPubMed
    1. Muller C,
    2. Goubin F,
    3. Ferrandis E,
    4. Cornil-Scharwtz I,
    5. Bailly JD,
    6. Bordier C,
    7. Benard J,
    8. Sikic BI,
    9. Laurent G
    : Evidence for transcriptional control of human MDR1 gene expression by verapamil in multidrug-resistant leukemic cells. Mol Pharmacol 47: 51-56, 1995.
    OpenUrlAbstract
  13. ↵
    1. Sulova Z,
    2. Macejova D,
    3. Seres M,
    4. Sedlak J,
    5. Brtko J,
    6. Breier A
    : Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol In Vitro 22: 96-105, 2008.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Wang Q,
    2. Wang T,
    3. Wang Y,
    4. Wang W,
    5. Wang Y,
    6. Hu X,
    7. Shao S,
    8. Zhang J,
    9. Suo Z
    : VP-16 resistance in the NCI-H460 human lung cancer cell line is significantly associated with glucose-regulated protein78 (GRP78) induction. Anticancer Res 27: 2359-2364, 2007.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Kim JR,
    2. Oh DR,
    3. Cha MH,
    4. Pyo BS,
    5. Rhee JH,
    6. Choy HE,
    7. Oh WK,
    8. Kim YR
    : Protective effect of polygoni cuspidati radix and emodin on Vibrio vulnificus cytotoxicity and infection. J Microbiol 46: 737-743, 2008.
    OpenUrlPubMed
  16. ↵
    1. Chen LM,
    2. Liang YJ,
    3. Zhang X,
    4. Su XD,
    5. Dai CL,
    6. Wang FP,
    7. Yan YY,
    8. Tao LY,
    9. Fu LW
    : Reversal of P-gp-mediated multidrug resistance by bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue. Anticancer Res 29: 4597-4604, 2009.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Pastan I,
    2. Gottesman M
    : Multiple-drug resistance in human cancer. N Engl J Med 316: 1388-1393, 1987.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bansal T,
    2. Jaggi M,
    3. Khar RK,
    4. Talegaonkar S
    : Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12: 46-78, 2009.
    OpenUrlPubMed
  19. ↵
    1. Hosey MM,
    2. Lazdunski M
    : Calcium channels: molecular pharmacology, structure and regulation. J Membr Biol 104: 81-105, 1988.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Breier A,
    2. Barancik M,
    3. Sulova Z,
    4. Uhrik B
    : P-glycoprotein–implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5: 457-468, 2005.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Triller N,
    2. Korosec P,
    3. Kern I,
    4. Kosnik M,
    5. Debeljak A
    : Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54: 235-240, 2006.
    OpenUrlCrossRefPubMed
    1. Gouaze V,
    2. Yu JY,
    3. Bleicher RJ,
    4. Han TY,
    5. Liu YY,
    6. Wang H,
    7. Gottesman MM,
    8. Bitterman A,
    9. Giuliano AE,
    10. Cabot MC
    : Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639, 2004.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Lagas JS,
    2. Fan L,
    3. Wagenaar E,
    4. Vlaming ML,
    5. van Tellingen O,
    6. Beijnen JH,
    7. Schinkel AH
    : P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 16: 130-140, 2010.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Murphy L,
    2. Henry M,
    3. Meleady P,
    4. Clynes M,
    5. Keenan J
    : Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochim Biophys Acta 1784: 1184-1191, 2008.
    OpenUrlPubMed
  24. ↵
    1. Johnstone RW,
    2. Cretney E,
    3. Smyth MJ
    : P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93: 1075-1085, 1999.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (9)
Anticancer Research
Vol. 30, Issue 9
September 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines
JIARUI WANG, HUILING WANG, LONG ZHAO, SUFANG FAN, ZHONGHAI YANG, FEI GAO, LIXIA CHEN, GARY GUISHAN XIAO, JOSEPH MOLNÁR, QI WANG
Anticancer Research Sep 2010, 30 (9) 3593-3598;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines
JIARUI WANG, HUILING WANG, LONG ZHAO, SUFANG FAN, ZHONGHAI YANG, FEI GAO, LIXIA CHEN, GARY GUISHAN XIAO, JOSEPH MOLNÁR, QI WANG
Anticancer Research Sep 2010, 30 (9) 3593-3598;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma
  • Roles of BCL-2 and MDR1 Expression in the Efficacy of Paclitaxel-based Lung Cancer Chemoradiation
  • Google Scholar

More in this TOC Section

  • Tumor Immunology Visualized in Realtime in In-vivo-like 3-D Gelfoam® Histoculture by Color-coded Imaging
  • The Role of EMP2 in Triple-negative Breast Cancer
  • Role of the Circadian Clock Gene DEC1 in Chemosensitivity and Apoptosis in Colorectal Cancer
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire